The demethylating 5-aza-2 0 deoxycytidine (DAC) and the histone deacetylase inhibitor (HDACi) suberoyl anilide bishydroxamide (SAHA) possess potent antitumorigenic properties in myeloid disorders. However, the transcriptome alterations mediated by these drugs are poorly understood. We analyzed the transcriptional effects of DAC and SAHA in the AML cell line KG-1. Microarray analyses revealed 76 genes expressed in normal CD34 þ cells, absent in KG-1 cells but whose expression was induced after drug treatment. A total of 39 of these genes harbored CpG islands in their promoters. We examined the expression level of these genes in 120 AML patient samples representing diverse karyotpyes. Gas2l1, tfIIs, ehd3, enolase 2, mx1, dral, astml and pxdn were diminished across all AML karyotypes examined. Ehd3 was methylated in 63% of AML patients examined. This methylation was lost upon complete remission, and not observed in normal CD34 þ cells. CD34 þ cells expressed ehd3 at approximately 10-fold higher levels than AML samples. Another highlighted gene, a-catenin, is located at q31 of chromosome 5. Analyses of 29 5q-AML/ myelodysplastic syndrome (MDS) samples revealed marked decreases in expression of a-catenin, compared to non-5q-MDS samples (6.679-fold). However, no methylation was detected, suggesting indirect effects of these drugs on the expression of a-catenin.
Introduction
Promoter regions of many genes contain clusters of CpG dinucleotides, referred to as CpG islands. These islands are generally protected from cytosine methylation. 1 Aberrant methylation of CpG residues in a promoter can lead to the recruitment of methyl-binding proteins (MBDs). These proteins recruit and complex with histone-modifying enzymes, resulting in the loss of expression of the associated gene product. 2 Many tumor suppressor genes can be silenced through aberrant DNA methylation in acute myeloid leukemias (AMLs). Among the most characterized are the cell-cycle inhibitors p15INK4b and p16INK4a, RARB2, SOCS-1 and CRBP1. 3, 4 The demethylating agent 5-aza-2 0 deoxycytidine (DAC) and the histone deacetylase inhibitor (HDACi) suberoyl anilide bishydroxamide (SAHA) have been shown to possess potent antitumorigenic properties against hematopoietic disorders. [5] [6] [7] [8] Recently, 5-aza-cytidine, DAC's parental compound, was approved by the Food and Drug Administration (FDA) for the treatment of myelodysplastic syndromes (MDSs); and many clinical trials are underway using either DAC or HDACis to treat AML. [9] [10] [11] [12] [13] However, no reports have examined their effects on global transcription in myeloid disorders. Understanding transcriptome alterations mediated by these drugs should prove vital in the elucidation of the mechanism(s) through which they mediate cell death. Furthermore, it will facilitate the uncovering of potential tumor suppressor genes, which have become epigenetically silenced in myeloid disorders, albeit either directly or indirectly.
To this end, we have examined the relative expression levels of over 22 000 genes in the AML cell line KG-1. Cells exposed to DAC and SAHA, as well as untreated populations, were subjected to a high-throughput microarray analysis of their transcriptome profiles in an attempt to determine the genetic reprogramming responsible for the antitumor properties of these drugs. Of the genes identified, we report one in particular whose expression was reduced across all subtypes of AML, the eps15 homology (EH) domain containing protein 3 (ehd3). The 5 0 regulatory region of ehd3 contains a CpG island that is aberrantly methylated in these cancers. Furthermore, we have demonstrated an association of this methylated CpG island with MBDs, the effectors of DNA methylation-mediated gene silencing.
Our study has also revealed a gene of potential importance in a specific subtype of myeloid disorders. Loss or deletion of the long arm of chromosome 5 (5q-or del(5q)) are common genetic abnormalities in myeloid malignancies.
14 Approximately 10% of de novo AML and MDS patients present with a 5q deletion. 15, 16 Here, we identify a gene located within common deleted regions (CDRs) of 5q31, a-catenin (CTNNA1), whose expression is induced by DAC and SAHA treatment in myeloid cell lines. Further analysis of the expression level of a-catenin in a panel of patients with either a 5q-AML or MDS showed that this gene was significantly decreased in expression when compared to non-5q-AML/MDS samples.
Materials and methods

Cells lines and patient samples
KG-1 17 cells were grown in Roswell Park Memorial Institute media 1640 with 10% fetal calf serum. Other myeloid leukemia cell lines (HL-60, NB-4, U937, THP1) were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA) and maintained according to their recommendations. Samples of 5q-AML/MDS and non-5q-AML/MDS were obtained from patients with informed consent. Diagnoses were based on the FAB classification (See Supplementary Information on the Leukemia website (http://www.nature.com/leu). DNA and RNA were extracted from formalin-fixed pellets basically as described by Coura et al. 18 with phenol-cholorform extraction of nucleic acid following proteinase K treatment.
Treatment with 5-Aza-CdR and SAHA
Cell lines were treated with DAC (Sigma, St Louis, MO, USA) and SAHA (Merck Inc., NJ, USA generous gift from Victoria Richon). Cells were cultured in the presence of DAC (1 mM) for 3 days; and on the second day, SAHA (1 mM) was added. Cells were harvested after a further 24 h of culture. Mock-treated cells were cultured similarly.
Microarray analyses
Total RNA (10 mg) was used as starting material for the cDNA preparation, which was performed as described previously. 19 cRNA (15 mg) was fragmented, hybridized to Affymetrix HG-U133A microarray (Santa Clara, CA, USA), scanned and analyzed as described previously. 19 Real-time RT-PCR, PCR and COBRA analyses RNA was prepared using RNeasy kits (Qiagen, Valencia, CA, USA) and real-time polymerase chain reaction (PCR) performed as described previously. 19 Amplification followed a three-step PCR with 10 s denaturation (941C), 10 s annealing (601C), elongation at 651C for 20 s and 5 s at melting temperature. PCR and combined bisulphite restriction analysis (COBRA) analyses of bisulphite-treated DNA were performed basically as described previously, 19 but using the enzyme BstU1. All primer sequences are available upon request.
Bisulphite sequencing
Bisulphite modification of DNA was performed using the EZ DNA Methylation Kit according to the manufacturer's recommendations (Zymo Research, Orange, CA, USA). PCR products were subcloned into pGEM-T Easy (Promega, Madison, WI, USA) for sequence analysis. At least six independent clones were sequenced in all samples analyzed. All primer sequences are available upon request.
Western blot analysis
Whole-cell lysates were prepared, resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis, transferred to polyvinylidene membrane (Immobilon, Amersham Corp., Arlington Heights, IL, USA) and visualized as described previously. 18 Membranes were probed with antibodies against a-catenin, b-catenin and glyceraldehyde-3-phosphate dehydrogenase (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
ChIP assay
Chromatin immunoprecipitations (ChIP) experiments were preformed as described previously, 19 using the ChIP assay kit (Upstate Inc., Chicago, IL, USA). Prepared lysates were incubated overnight, at 41C, with 5 mg of antiacetylated lysine antibody (Upstate, Charlottesville, VA, USA), anti-MeCP2 antibody (Upstate), anti-MBD2/3 antibody (Upstate), anti-HA antibody (Santa Cruz, CA, USA) or normal rabbit serum. Immunoprecipitated DNA was ultimately recovered by phenol/chloroform extraction and ethanol precipitation and analyzed by PCR and gel electrophoresis. The optimal reaction conditions for PCR were determined for each primer pair (sequences available upon request).
Results
Determination of genes induced by DAC and SAHA treatment in myeloid leukemia cells
Using the HG-U133A microarray platform, we identified genes upregulated in the AML cell line KG-1 after treatment with the DNA methylation inhibitor DAC (1 mM, 72 h) and the HDACi SAHA (1 mM, 24 h). In an attempt to increase the relevance of the results of the array experiment, we modified a gene selection method first described by Yamashita et al.
20 Figure 1 depicts the selection criteria used to bias the final gene list towards genes whose expression was likely altered through epigenetic mechanisms in leukemia. Of the probe sets examined, 3837 were differentially expressed between the treated and untreated populations by at least twofold, and with a significance of Po0.05. In keeping with the hypothesis that epigenetically silenced (directly or indirectly) tumor suppressor genes are re-expressed in this experimental model, only probe sets called present in the treated samples (2204) and also absent in the untreated samples (492) were examined further. KG-1 cells are an early myeloid progenitor cell line, which retains the expression of the CD34 antigen. This cell line, therefore, is most suitable for a comparison to the normal CD34 þ hematopoietic cell population. In these normal cells, we would reason that any tumor suppressor genes relevant to this stage of hematopoiesis would be expressed. We compared the expression level of the aforementioned 492 genes against HG-U133A microarray expression data obtained from three independent normal CD34 þ cell populations. 21 A total of 95 of the 492 probe sets were expressed in normal CD34 þ cells, of which 39 were genes that contained CpG islands in their 5 0 regulatory regions (http://genome.ucsc.edu/). The expression levels of a subset of these 39 genes in the treated and untreated KG-1 cell populations were validated by real-time RT-PCR, which confirmed the microarray data (data not shown).
To complete the paradigm, we reasoned that a tumor suppressor gene would also not be expressed in primary leukemias. We cross-referenced the expression status of these 39 genes against a panel of primary AML patient samples for which we had access to HG-U133A expression data. 20 samples of each of the following AML karyotypes were analyzed: t,(8;21) t,(15:17) inv, 16 11q23/MLL, complex and normal karyotype. The results are described in Table 1 . Of special note, expression of eight genes was markedly diminished in a subset of patients across all AML karyotypes examined: GAS2L1, TFIIS, EHD3, enolase 2, MXA, DRAL, ASTML and PXDN. These represent strong candidates for tumor suppressor genes in AML.
Identification of methylation through bisulphite sequencing and methyl-binding protein association in the 5 0 regulatory regions of target genes
Bisulphite sequencing analyses of the 5 0 regulatory regions of a number of promising genes in Table 1 were performed using genomic DNA of KG-1 cells in order to detect the presence of aberrant methylation. Multiple clones (at least six) were sequenced for the promoter CpG islands of DRAL, ASTML, Id2 and enolase 2. Unexpectedly, no CpG methylation was detected in any of these gene promoters, despite the stringent selection criteria imposed in the original (data not shown) screen. These findings were not just a KG-1 cell line phenomenon, as bisulphite sequencing for these CpG islands was performed on three AML patient genomic DNA samples with the same result (data not shown).
These data made clear that DAC and SAHA treatment was affecting the transcription of many genes irrespective of their methylation status. We developed a ChIP technique to screen for methylated genes in our list of tumor suppressor candidates. ChIPs were performed on KG-1 cells using antibodies raised against the DNA methyl-binding protein MeCP2, as well as MBD2 and MBD3 (MBD2/3). These proteins are known to bind methylated CpGs in the promoter regions of genes and transduce these repressive marks into silencing of the gene through the recruitment of histone-modifying enzymes.
22 Figure 2 shows the result of a screen on a selection of candidate genes. All ChIPs with the control anti-HA antibody were negative. An anti-acetyl lysine antibody was used as a positive control. PCR amplicons corresponded to the CpG island in the promoter regions of the target genes. The p15 tumor suppressor gene has been shown to be methylated in 75% of AML samples and to exist as a functionally repressive, variegated promoter methylation in KG-1 cells. Here, we validate our ChIP approach by demonstrating an association of the p15 promoter with both the MBD2/3 and MeCP2 proteins. Both tfiis2 and id2 were associated with the transcriptionally permissive chromatin mark and not bound by MBDs. In the case of id2, this was expected as we had already demonstrated lack of methylation in its CpG promoter island (data not shown). However, the promoter CpG islands of mxa and ehd3 were associated with the MBDs. In the case of mxa, the association was weak, but reproducible. Ehd3 promoter binding to MBD2/3 and MeCP2 was very robust, and this gene was chosen for further study.
EHD3 is methylated in AML samples.
The CpG island in the 5 0 regulatory region of ehd3 was analyzed in KG-1 cells, normal CD34 þ cells and three AML patient samples by bisulphite sequencing. Genomic DNA was isolated and modified through sodium bisulphite treatment. Figure 3a depicts the sequencing results of five distinct clones for each cell type. All CpG dinucleotides analyzed in KG-1 cells were methylated at the cytosine residue, as represented by black circles, confirming the inference of the ChIP experiments (Figures 2 and 3a) . The restriction enzyme BstU1 recognizes and cuts DNA at CGCG sites. The CpG island of ehd3 contains four such BstU1 restriction sites (Figure 3a , black boxes), making it possible to screen for methylation in this island using COBRA. COBRA analysis of this promoter region was validated using these five samples. Figure 3b shows representative restriction digests of ehd3 promoter PCR products from bisulphite-treated genomic DNA. The KG-1 PCR product was completely digested by BstU1, as the sequencing results predicted. The product from normal CD34 þ cells was not digested. Interestingly for the AML patient samples, the amount of digested PCR product appeared to correlate with the level of methylation observed in the sequencing results with no digestion observed in the product from patient No. 3, slight digestion in the sample from patient No. 1 and robust digestion of the PCR product derived from patient No. 2's DNA (Figure 3a and b) . To confirm further the sensitivity of the COBRA analysis and its dependence on a methylated starting template, the acute promyelocytic leukemiaderived cell line NB4 was cultured in the presence and absence of DAC for 72 h, and COBRA analysis was subsequently performed on the ehd3 promoter region. Figure 3c demonstrates that this CpG island is also methylated in NB4 cells, and that this methylation is reduced upon treatment of the cells with DAC.
COBRA was then used to screen a larger population of primary AML samples for ehd3 methylation. Figure 3d shows representative BstU1 digests of ehd3 promoter region after PCR products were amplified from bisulphite-treated DNA of patient samples. Eight out of 13 patient samples screened solely by COBRA, were positive for ehd3 CpG island methylation. Interestingly, we obtained complete remission (CR) samples from patients No. 4 and No. 5, which showed no evidence of methylation even though the PCR products from both the corresponding disease samples were digested by BstU1 (methylated gene) (Figure 3d ). Overall, 10 out of 16 (63%) of the primary AML samples showed ehd3 promoter methylation, whereas no methylation was detected in a purified normal CD34 cell population or in two disease-free remission samples.
AML patient samples express low levels of EHD3 as compared to CD34 þ cells from healthy donors 
a-Catenin is induced by DAC and SAHA treatment
Although not absent in any of the AML samples investigated (Table 1) , a-catenin (CTNNA1) is located on chromosome 5, in the commonly deleted region (CDR) of 5q-MDS and AML. Several groups have delineated a CDR on chromosome 5, but a gene contributing to these disorders in this region has yet to been identified. 23, 24 We decided to characterize the methylation and expression status of a-catenin in 5q-MDS and AML samples. The increase in a-catenin mRNA expression in response to DAC and SAHA treatment was confirmed through real-time RT-PCR analysis. Figure 5a shows an increase in a-catenin transcript levels in all four myeloid cell lines. U937 cells showed the greatest elevation of a-catenin expression, with A n t i M e C P 2 A n t i -a c e t y l l y s i n e
Id2
MXA Figure 2 ChIP analyses of methyl-binding protein association with the 5 0 regulatory regions of identified target genes. KG1 cells were subjected to crosslinking with formaldehyde and chromatin fractions were prepared by sonication. DNA was purified from immunoprecipitations with antibodies against acetylated lysine, MBD 2/3 and MeCP2, as described in Materials and methods. Anti-HA antibody and no antibody ChIPs were performed as negative controls. DNA eluates were analyzed with primers designed to the CpG islands of the target genes. A total of 35 cycles of PCR were performed in all cases. PCR products were analyzed by agarose gel (2%) electrophoresis.
DAC and SAHA increasing mRNA levels by 4.270.2-fold. Combined drug treated KG-1 cells exhibited a 2.370.2-fold increase over untreated control cells mimicking the 2.8-fold increase observed in the microarray analysis ( Figure 5a and Table 1 ). Importantly, Western blot studies showed that this increase of a-catenin in KG-1 cells was also observed at the protein level (Figure 5b ). Bisulphite PCR analyses were performed on the CpG island in the promoter region of a-catenin using genomic DNA isolated from KG-1 and normal CD34 þ cells. No methylated cytosines were found in any of the 100-CpG dinucleotides examined in this island (five clones sequenced for each cell type). Furthermore, no methylation was detected in three 5q-MDS and three 5q-AML patient samples (data not shown).
a-Catenin expression is markedly diminished in 5q-MDS and AML
Real-time RT-PCR analyses of a-catenin transcript levels were performed on 29 5q-MDS and AML patient samples as compared to transcript levels in 21 non-5q-MDS and AML samples. In Figure 6a results are graphed as relative to the mean of the 5q-MDS and AML samples (171.7). Non-5q-MDS/AML samples showed variable a-catenin expression levels; but as a population, the expression was significantly higher than that observed in the 5q-samples. The mean increase in a-catenin transcript levels in the non-5q-MDS/AML samples was 6.5779.3 fold greater than those in the 5q-MDS/AML samples (Po0.01). Figure 6b depicts these results in the form of a dot plot. The expression levels of genes in the immediate vicinity of a-catenin on chromosome 5 were also examined in these same samples. A sample was scored positive for gene expression if a PCR product was observed at 25 cycles of RT-PCR. Table 2 summarizes the results of these reactions. Sample concentrations were normalized by RT-PCR, and b-actin expression.
In general, deletion of 5q-chromosomal material resulted in a 1.5-fold decrease in samples expressing these genes at 25 cycles of RT-PCR. However, only one of 29 (3.5%) samples was positive for expression of the a-catenin gene in the 5q-patient group, as compared to six out of 16 (38%) in the non-5q-sample set. This represents a 10.7-fold decrease in expression between the two groups, which is approximately sevenfold less than any of the neighboring genes on chromosome 5 ( Table 2 ). These results suggest that a-catenin is silenced in the 5q-samples to a level that exceeds what would be expected by haploinsufficiency alone.
Discussion
Epigenetic alterations play a crucial role in the silencing of genes. Hypermethylation of cytosine residues in the CpG islands of gene promoters has been shown to result in the silencing of gene transcription. The elucidation of genes epigenetically silenced in cancers is dramatically advancing our understanding of these diseases and facilitating the search for new treatment regimes. Although the list of known methylated genes associated with human leukemias is growing, 3 many epigenetically silenced tumor suppressor genes probably remain undiscovered in these disorders.
Drugs that are able to reverse these epigenetic modifications are enjoying notable success in the treatment of these disorders. Specifically, the demethylating agents 5-aza-cytidine (Vidaza) and DAC (Dacogen) and the HDACi SAHA have been shown to possess potent antitumorigenic properties against hematopoietic disorders.
5-8 Both 5-aza-cytidine and DAC have been approved by the FDA for use in MDS. Furthermore DAC has undergone successful MDS trials in Europe. [10] [11] [12] [13] 25 The successes of these drugs intuitively points to their ability to remove transcriptionally repressive marks from chromatin in the vicinity of tumor suppressor genes. However, these drugs are also likely to elicit a wide range of effects upon transcription.
In this study, we attempted to uncover novel tumor suppressor genes through their activation by DAC and SAHA by modifying an approach used by Yamashita et al. 20 Importantly, although we utilized several gene selection steps designed to uncover genes directly methylated in this disorders, this did not preclude our characterization of any potential tumor suppressor whose activation appeared independent of its DNA methylation status.
Using the Affymetrix HG-U133A microarray platform, the relative expression levels of over 22 000 genes were compared between untreated KG-1 cell populations and KG-1 cells treated with the DNA demethylating drug, DAC, and the HDACi SAHA. Stringent statistical analyses performed on the resulting data revealed 492 probe sets that represented genes ordinarily silenced in KG-1 cells, but whose transcription was induced following the reversal of the epigenetic phenotype of the cells. We reasoned that any tumor suppressor genes would, by definition, be expressed in normal CD34 þ cells. Using microarray analyses, we determined the expression status of these 492 probe sets in three CD34 þ cell populations purified from the bone marrow of three independent healthy donors. A total of 95 of the probe sets were expressed in the normal cell populations, 39 of which were genes that harbored 5 0 regulatory CpG islands. It should be noted that the treatment of KG-1 cells with this drug combination also lead to significant number of probe sets being downregulated, as compared to untreated control cell populations. This phenomenon, beyond the remit of this study, merits further study.
A thorough analysis of the expression status of these genes in leukemia patient samples was performed using microarray data obtained from 120 AML patients. Six groups of 20 patients were selected for screening, based upon the overriding karyotype of their disease. Eight genes were noted for their low expression levels across the spectrum of AML karyotypes examined: gas2l1, tfIIs, ehd3, enolase 2, mxA (mx1), dral, astml and pxdn. Furthermore, there were genes whose expression was markedly diminished in specific AML subsets. For example, cd9 was absent in 75% of cases of t(8;21) AMLs, and fh1 and fxyd6 were absent in 60 and 55% of samples of t(15;17)s, respectively. D2s488 was not expressed in 60% of inv (16)s, 50% of AMLs with normal karyotype and 45% of AMLs with MLL translocations (11q23). Although beyond the scope of this study, these genes should be considered for more focused analyses in these specific AML subtypes.
Surprisingly, bisulphite sequencing analyses did not detect any methylation in any samples for the promoter regions of dral, astml, enolase 2 or id2; id2 chosen for further study owing to its known involvement in myeloid development. 26 These findings supported our initial supposition that these treatments would have wide-ranging effects on gene transcription, not limited to genes directly epigenetically silenced. Similar findings have been reported elsewhere. 27 Furthermore, as the drugs were used in combination, it is possible that DAC does not play a role in the activation of these genes.
Methylated-CpG dinucleotides associate with MBDs, which in turn, modulate transcription through the recruitment of histone-modifying enzymes. 2 We reasoned that any of our candidate genes harboring functionally relevant methylation in their promoter regions would be associated with one, or more of these proteins. ChIPs were performed on KG-1 (untreated) cells using antibodies raised to the three MBDs most commonly associated with methyl-CpG binding in humans, MBD2 and MBD3 (dual specific antibody) and MeCP2. Of the candidate genes examined, the most striking association was found with the promoter region of ehd3. In this assay, ehd3 promoter DNA was found enriched in both the MBD2/3 and MeCP2 immunoprecipitations, suggesting robust methylation of this promoter in KG-1 cells.
The CpG island of ehd3 was amplified and clonal sequencing was performed. Confirming the ChIP experiment, the ehd3 promoter of KG-1 cells was completely methylated. Strikingly, the same region was completely unmethylated in the normal CD34 þ cell population. Furthermore, methylation of the ehd3 promoter was found in all three AML patient samples, to varying degrees. Using COBRA analysis, 13 more AML patient samples were analyzed for ehd3 methylation. Methylation was observed in eight out of 13 of these patients. Moreover, two patients showed methylation in samples taken during active disease, but none was observed in samples taken from the same individuals after they had entered CR. This implied that the methylation of ehd3 was restricted to the cancerous cells in these patients and not present in their normal cells. In summary, across the different detection methods, 16 primary AML samples were analyzed and methylation of the ehd3 promoter was observed in 10 patients (63%). All normal samples, either purified normal CD34 þ cells or normal patient blood samples, were negative for ehd3 methylation. Furthermore, methylation of this promoter in NB4 cells could be reversed by 72 h DAC treatment, as analyzed by COBRA (Figure 3c ). Expression levels of ehd3 mRNA were examined in a separate panel of AML patient samples. Real-time RT-PCR revealed expression levels of ehd3 in AML blast cells to be dramatically lower than those observed in normal CD34 þ cells. Normal CD34 þ cells expressed ehd3 transcripts at approximately 10-fold higher levels than those observed in the AML samples (Po0.005).
These data clearly show that ehd3, a gene expressed in normal CD34 þ cells, is methylated and repressed, in a significant proportion of AML patient's blast cells. Ehd3 thus represents a prime candidate as a novel tumor suppressor gene in this disease. Biologically, EHD3 (EH domain containing protein 3) is involved in the shuttling of endocytic vesicles. The protein appears to be a feature of the endocytic recycling compartment (ERC), as it has been shown to colocalize with transferrin containing recycling vesicles. 28, 29 A recent study has demonstrated that RNAi-mediated knockdown of EHD3 in HeLa cells results in the failure of internalized transferrin to localize to the ERC, instead remaining contained in large, peripheral organelles. 30 In the same study, the authors note recent evidence implying that blocking vesicle trafficking to the ERC may, in fact, increase the rate of recycling. This is thought to occur through a 'fast recycling' pathway. 31 It is unclear as to the effects of loss of EHD3 in myeloid cells, but it is interesting to note various studies that show an involvement of transferrin and/or the transferrin receptor levels in the pathogenesis of AMLs. 32, 33 Furthermore, the elucidation of other cargo contained within EHD3-associated endosomes may provide crucial insights into the pathogenesis of various AMLs.
Loss or deletions of the long arm of chromosome 5 (-5/5q-) are common genetic abnormalities in myeloid malignancies. 14 The most frequent occurence of 5q-is in secondary, therapy-related leukemias and MDSs (tAML, tMDS), where deletion is observed in over 43% of cases.
16 5q-leukemia is typified by poor response to chemotherapy and CR rates of under 30%. 34 a-Catenin is located on chromosome 5, in the CDR of 5q-MDS and AML. Several groups have delineated a CDR on chromosome 5, but a gene contributing to these disorders in this region has yet to be identified. 15, 24, 35 As a-catenin was on our list of 39 genes, we decided to characterize the methylation and expression status of a-catenin in 5q-MDS and AML samples. Given the lack of a good 5q-cell model system, myeloid leukemia cell models systems were used. Both a-catenin mRNA and protein expression levels increased in response to DAC and SAHA treatment. a-Catenin transcript levels increased in all four myeloid cell lines examined. mRNA levels in U937 cells increased by 4.270.2-fold. Combined drug-treated KG-1 cells exhibited a 2.370.2-fold increase over untreated control cells mimicking the 2.8-fold increase observed in the microarray analysis. Western blot analyses demonstrated that the increase of a-catenin seen in KG-1 cells was also observed at the protein level. Moreover, a-catenin protein was undetectable in the untreated KG-1 cells, implying that gene transcription is turned on by DAC and SAHA at this locus, rather than merely augmented. Bisulphite PCR analyses were performed on the CpG island located in the promoter region of a-catenin. Using genomic DNA isolated from KG-1 and normal CD34 þ cells, none of the cytosines were found to be methylated in any of the 100 CpG dinucleotides examined (five clones sequenced for each cell type). Furthermore, no methylation was detected in three 5q-MDS and three 5q-AML patient samples (data not shown). Real-time RT-PCR analyses of a-catenin transcript levels were performed on 29 5q-MDS and AML patient samples. These results were compared to observed transcript levels in 21 non-5q-MDS and AML samples. Non-5q-MDS / AML samples showed variable a-catenin expression levels; but as a population, their expression was significantly higher (6.5779.3 fold) than that observed in the 5q-MDS/AML samples (Po0.01). Furthermore, expression of genes in the immediate vicinity of acatenin was not diminished to the same degree in the 5q-MDS versus non-5q-MDS samples, suggesting that a-catenin is silenced to a level that exceeds what would be expected by haploinsufficiency alone in the 5q-samples. Taken together, these results imply an indirect effect of DAC and SAHA on the expression of the a-catenin gene.
a-Catenin is part of the adheren junction protein complex in mammalian cells. It binds and links b-catenin to the cellular cytoskeleton. 36 Its role in stabilizing this complex may point to a mechanism whereby loss of a-catenin protein could promote either cellular growth or transformation. By destabilizing b-catenin at the cell surface, loss of a-catenin could promote its nuclear translocation and the subsequent activation of oncogenic b-catenin target genes. 37 However, our experiments showed no changes in b-catenin localization in myeloid cell lines upon treatment with DAC or SAHA (data not shown). Furthermore, no changes in b-catenin-mediated transcription were observed in U937 cells transfected with the TOP and FOP FLASH TCF/LEF b-catenin reporter constructs (data not shown). Recently, a-catenin has been reported to play a role in symmetry maintenance in stem cells. 38 Loss of a-catenin in primitive CD34 þ myeloid progenitor cells could possibly lead to asymmetrical cell division, resulting in a dysplastic myeloid cell population.
In summary, the use of drugs engineered to reverse epigenetic phenotype in myeloid cells results in the activation of genes independent of their CpG-island methylation status. We have uncovered a group of genes expressed in normal CD34 þ cells, and whose transcription is reinduced upon DAC and SAHA treatment in KG1 cells. Our results identify ehd3, as a gene whose expression is markedly dimished in a host of AMLs, seemingly through the hypermethylation of the CpG island in its promoter region. In addition, we also identify a-catenin as a gene deregulated through an epigenetic event(s) in 5q-related myeloid disorders.
